Zydus Cadila receives USFDA approval for Hydroxychloroquine Sulfate Tablets
A Journey of Growth


• After an existence of five decades, Cadila Laboratories restructures its operations in 1995. Cadila Healthcare Limited comes into being under the aegis of Zydus Group.


• Cadila Healthcare launches Falcigo in strategic alliance with Gulin Pharma of China. This breakthrough product in the anti-malarial segment was launched for the first time in India in 1996, Soars to the 9th position from the 16th position in ORG rankings within just a year of restructuring.


• Registers the fastest growth amongst the top 80 Indian pharma companies in 1997.


• In 1998, the group enters into a joint venture with Altana Pharma AG of Germany, a research-driven pharma major to create a new joint venture company Zydus Altana Healthcare Pvt. Ltd.


• The API plant at Ankleshwar receives ISO 9002 certificate in the year 1999.


• Cadila Healthcare enters the capital market with an IPO in February 2000.

• Acquires formulation business of Recon Ltd. in May 2000. This strategic move boosted the growth of the formulation business, further consolidating the group’s strengths in the southern markets.

• The API plant at Ankleshwar receives ISO 14001 certification in December 2000.


• Acquires German Remedies Ltd. in 2001, which was the largest M&A in the Indian pharmaceutical sector. Becomes  the  4th largest group in the Indian pharma industry.

• Zydus Cadila and U.S. based Onconova enter into a joint venture in 2001 for collaborative research in the field of oncogenomics.

• Zydus Cadila acquires 'Aten', one of India's largest selling anti-hypertensive brands in 2001. The acquisition catapults Zydus Cadila to the top spot in the cardiovascular segment.


• Acquires Banyan Chemicals, a Vadodara based company with a US FDA approved plant in April 2002.

• The manufacturing premises at Moraiya receives approval from the Medicine Control Agency of U.K., now known as MHRA, in April 2002.

• Launches two in-house programmes: ‘Prism’- a cost savings programme and ‘Delta’- a value creation programme.

• State-of-the-art formulation manufacturing plant at Moraiya receives approval from Brazilain regulatory agency ANVISA. This certification qualifies Zydus Cadila to enter the Brazilian market with its oral tablets, capsules and soft gelatine capsules.

• Mega merger of German Remedies, Recon Healthcare, Zoom Properties and Zydus Pathline with Cadila Healthcare Limited.


• Acquires Alpharma France in 2003. Now known as Zydus France SAS, the company spearheads Zydus Group’s operations in France, one of the fastest growing markets in Europe.

• Emerges as a ‘Partner of Choice’ for Schering AG, a leading global pharma healthcare segment, to manufacture and market existing products of the company in India.

• In a two-pronged strategy for the U.S. market, establishes Zydus Healthcare (U.S.A) LLC to market APIs in the U.S. market in 2002 and Zydus Pharmaceuticals (U.S.A) Inc. to market formulations generics business in the U.S.A  in 2003.

• Files 12 ANDAs with the US FDA in 2003-04, making it the first Indian company with the largest number of filings in the very first year.

• Enters into a joint venture with Sarabhai Enterprise in the Animal Healthcare segment, to create India’s number one animal healthcare company – Sarabhai Zydus Animal Health Ltd.


• The state-of-the-art formulations manufacturing plant at Moraiya and API plant at Dabhasa received approvals from the US FDA.

• Enters the French generics market with 43 generics.

• In November 2004, enters into a strategic alliance with Zambon Group, one of the leading multinational groups of Italy to open up new avenues in contract manufacturing.

• ATEN becomes the 1st Zydus brand to storm into the Top-20 pharma brand ranking (ORG:Oct).

• Nucoxia, the first Etoricoxib brand to be launched in 2004 in India becomes the ‘Best Launch of the Year’ from amongst 2200 new brands(ORG:Dec, MAT 2004).The other best launches from Zydus Cadila were Mifegest, Penegra, Revaldo, Levoday and Novospar.

• Retains No.1 position in CVS, GI and Women’s Healthcare participated segments in the Indian pharma market (ORG:Mar,MAT 2004).

• Enters into a long term strategic pact with Boehringer Ingelheim India Limited, a wholly owned subsidiary of Boehringer Ingelheim (BI) to manufacture and market BI’s product in India.


• Receives five product approvals from the US FDA to market Atenolol, Clindamycin, Metformin Hydrochloride Tablet, Metformin EX and Metformin ER.

• Enters into a strategic alliance with Mallinckrodt Pharmaceuticals Generics, a business unit of Tyco Healthcare and the 7th largest generic pharmaceutical company in the U.S. As per the agreement, the generic products manufactured by Zydus Cadila will be marketed by Mallinckrodt under a joint label.

• Signs a Joint Venture Agreement with Mayne Pharma - a leading injectable speciality pharmaceuticals company based in Australia to set up a 50:50 joint venture to manufacture Generic Injectable Cytotoxic (anti-cancer) medicines as well as Active Pharmaceutical Ingredients (API) for global markets.

• Signs a Joint Venture Agreement with Bharat Serums and Vaccines Limited (BSV), one of the leading Biotech companies in India to set up a 50:50 joint venture company to develop, manufacture and market a non-infringing and proprietary Novel Drug Delivery System (NDDS).

• Receives approval from Drug Controller General on India (DCGI) for its first Investigational New Drug (IND) application for the New Molecular Entity (NME)-ZYH1.


• Zydus Cadila acquires 14.96% stake in Carnation Nutra-Analogue Foods Ltd., the manufacturers of Nutralite - India’s largest selling cholesterol-free margarine.

• Zydus Cadila files IND application for NME - ZYH2, a novel agent for treating diabetes and for NME – ZYO1, a novel drug candidate for treating obesity and related disorders with the DCGI.

• Receives permission from Drug Controller General of India (DCGI) to conduct Phase II clinical trials on its NME – ZYH1, a novel agent for treatment of metabolic disorders and to conduct Phase II clinical trials on its NME – ZYH2.

• German Remedies launches ‘Novolizer’ – a patented  device for Asthma and COPD.


• Launches 39 new products (including line extensions) in India during the year, of which 8 were 1st to launch.

• Enters Rs. 1500 Cr. dermatology market, with acquisition of Mumbai based Liva Healthcare Ltd., which has a wide product portfolio in the dermatology segment.

• Acquires Nippon Universal Pharmaceuticals Ltd. of Japan, thus getting critical access to a ready manufacturing and marketing base as well as a distribution network.

• Files fourth Investigational New Drug application (IND) with the DCGI for ZYO1, a novel drug candidate for treating obesity and related disorders.

• Announces its second overseas acquisition in June 2007, acquiring 100% stake in Quimica e Farmaceutica Nikkho do Brasil Ltda. (Nikkho), a mid-sized, privately held company in Brazil.


• Files fifth IND with DCGI for ZYH7, a novel drug candidate for treating dyslipidemia and metabolic disorders.
Copyright © Zyduscadila.com All rights reserved.